tbuckley/cabot-search huggingface dataset:
Profilin 1 delivery tunes cytoskeletal dynamics toward CNS axon regeneration
Authors: Rita Pinto-Costa, Sara C. Sousa, Sérgio C. Leite, Joana Nogueira-Rodrigues, Tiago Ferreira da Silva, Diana Machado, Joana Marques, Ana Catarina Costa, Márcia A. Liz, Francesca Bartolini, Pedro Brites, Mercedes Costell, Reinhard Fässler, Mónica M. Sousa
Journal: Journal of Clinical Investigation (2020)

After trauma, regeneration of adult CNS axons is abortive, causing devastating neurologic deficits. Despite progress in rehabilitative care, there is no effective treatment that stimulates axonal growth following injury. Using models with different regenerative capacities, followed by gain- and loss-of-function analysis, we identified profilin 1 (Pfn1) as a coordinator of actin and microtubules (MTs), powering axonal growth and regeneration. In growth cones, Pfn1 increased actin retrograde flow, MT growth speed, and invasion of filopodia by MTs, orchestrating cytoskeletal dynamics toward axonal growth. In vitro, active Pfn1 promoted MT growth in a formin-dependent manner, whereas localization of MTs to growth cone filopodia was facilitated by direct MT binding and interaction with formins. In vivo, Pfn1 ablation limited regeneration of growth-competent axons after sciatic nerve and spinal cord injury. Adeno-associated viral (AAV) delivery of constitutively active Pfn1 to rodents promoted axonal regeneration, neuromuscular junction maturation, and functional recovery of injured sciatic nerves, and increased the ability of regenerating axons to penetrate the inhibitory spinal cord glial scar. Thus, we identify Pfn1 as an important regulator of axonal regeneration and suggest that AAV-mediated delivery of constitutively active Pfn1, together with the identification of modulators of Pfn1 activity, should be considered to treat the injured nervous system.
Developing Prognostic Biomarker of Breast Cancer using Expression Profile about TP53 Status
Authors: S. Takahashi, M. Inoue, T. Fukui, N. Gondo, S. Yokoyama, T. Ishida, N. Ohuchi, T. Nomizu, Y. Kakugawa, C. Ishioka
Journal: Annals of Oncology (2012)
Temporal Trends in Critical Care Outcomes in U.S. Minority-Serving Hospitals
Authors: John Danziger, Miguel Ángel Armengol de la Hoz, Wenyuan Li, Matthieu Komorowski, Rodrigo Octávio Deliberato, Barret N. M. Rush, Kenneth J. Mukamal, Leo Celi, Omar Badawi
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Whether critical care improvements over the last 10 years extend to all hospitals has not been described.
Reporting of the Medical Licensing Examination
Authors: Robert Battisti
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Authors: Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Journal: Clinical Cancer Research (2020)

Thymidine kinase 1 (TK1) is downstream to the CDK4/6 pathway, and TK activity (TKa) measured in blood is a dynamic marker of outcome in patients with advanced breast cancer (ABC). This study explores TK1 as a biomarker of palbociclib response, both in vitro and in patients with ABC.Modulation of TK1 levels and activity by palbociclib were studied in seven estrogen receptor-positive breast cancer cell lines: sensitive (PDS) and with palbociclib acquired resistance (PDR). TKa was assayed in plasma obtained at baseline (T0), after one cycle (T1), and at disease progression on palbociclib (T2) in patients enrolled in the "To Reverse ENDocrine Resistance" (TREnd) trial (n = 46).Among E2F-dependent genes, TK1 was significantly downregulated after short-term palbociclib. Early TKa reduction by palbociclib occurred in PDS but not in PDR cells. In patients, median TKa (mTKa) at T0 was 75 DiviTum units per liter (Du/L), with baseline TKa not proving prognostic. At T1, mTKa decreased to 35 Du/L, with a minority of patients (n = 8) showing an increase-correlating with a worse outcome than those with decreased/stable TKa (n = 33; mPFS 3.0 vs 9.0 months; P = 0.002). At T2, mTKa was 251 Du/L; patients with TKa above the median had worse outcomes on post-study treatment compared with those with lower TKa (2.9 vs 8.7 months; P = 0.05).TK is a dynamic marker of resistance to palbociclib which may lead to early identification of patients in whom treatment escalation may be feasible. In addition, TKa may stratify prognosis in patients with acquired resistance to palbociclib.
P-0300 Preoperative Concomitant Chemoradiotherapy with Capecitabine in Locally Advanced Rectal Carcinoma: Results at 3 Years
Authors: Fatema Zohra Boudinar, Abdelbaki Bukerche, Blaha Larbaoui, Ahmed Fethi Dali-Youcef
Journal: Annals of Oncology (2012)
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study
Authors: Daniel W. Lin, Mei-Chiung Shih, William Aronson, Joseph Basler, Tomasz M. Beer, Mary Brophy, Matthew Cooperberg, Mark Garzotto, W. Kevin Kelly, Kelvin Lee, Valerie McGuire, Yajie Wang, Ying Lu, Vivian Markle, Unyime Nseyo, Robert Ringer, Stephen J. Savage, Patricia Sinnott, Edward Uchio, Claire C. Yang, R. Bruce Montgomery
Journal: European Urology (2020)
Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of <i>ERBB2</i>-Positive Breast Cancer
Authors: Anthony F. Yu, Jessica R. Flynn, Chaya S. Moskowitz, Jessica M. Scott, Kevin C. Oeffinger, Chau T. Dang, Jennifer E. Liu, Lee W. Jones, Richard M. Steingart
Journal: JAMA Cardiology (2020)

Trastuzumab improves outcomes in patients with ERBB2-positive (formerly HER2) breast cancer but is associated with treatment-induced cardiotoxicity, most commonly manifest by an asymptomatic decline in left ventricular ejection fraction (LVEF). Little is known to date regarding the long-term effects of treatment-induced cardiotoxicity on cardiopulmonary function in patients who survive trastuzumab-treated breast cancer.To determine whether treatment-induced cardiotoxicity recovers or is associated with long-term cardiopulmonary dysfunction in survivors of ERBB2-positive breast cancer.This cross-sectional case-control study enrolled patients with nonmetastatic ERBB2-positive breast cancer after completion of trastuzumab-based therapy (median, 7.0 [interquartile range (IQR), 6.2-8.7] years after therapy) who met 1 of 2 criteria: (1) cardiotoxicity (TOX group) developed during trastuzumab treatment (ie, asymptomatic decrease of LVEF≥10% from baseline to <55% [n = 22]) or (2) no evidence of cardiotoxicity during trastuzumab treatment (NOTOX group [n = 20]). Patients were treated at the Memorial Sloan Kettering Cancer Center. Fifteen healthy control participants (HC group) were also enrolled for comparison purposes. All groups were frequency matched by age strata (<55, 55-64, and ≥65 years). Data were collected from September 9, 2016, to August 10, 2018, and analyzed from November 20, 2018, to August 12, 2019.Speckle-tracking echocardiography and maximal cardiopulmonary exercise testing were performed to measure indices of left ventricular function (including LVEF and global longitudinal strain [GLS]) and peak oxygen consumption (peak VO2).A total of 57 participants (median age, 60.8 [IQR, 52.7-65.7] years) were included in the analysis. Overall, 38 of 42 patients with breast cancer (90%) were treated with anthracyclines before trastuzumab. Resting mean (SD) LVEF was significantly lower in the TOX group (56.9% [5.2%]) compared with the NOTOX (62.4% [4.0%]) and HC (65.3% [2.9%]) groups; similar results were found for GLS (TOX group, -17.8% [2.2%]; NOTOX group, -19.8% [2.2%]; HC group, -21.3% [1.8%]) (P < .001). Mean peak VO2 in the TOX group (22.9 [4.4] mL/kg/min) was 15% lower compared with the NOTOX group (27.0 [5.3] mL/kg/min; P = .03) and 25% lower compared with the HC group (30.5 [3.4] mL/ kg/min; P < .001). In patients with breast cancer, GLS was significantly associated with peak VO2 (β coefficient, -0.75; 95% CI, -1.32 to -0.18).Treatment-induced cardiotoxicity appears to be associated with long-term marked impairment of cardiopulmonary function and may contribute to increased risk of late-occurring cardiovascular disease in survivors of ERBB2-positive breast cancer.
Abstract 15398: Genetic, Epigenetic, and Transcriptional Variations at NFATC2IP Locus With Weight Loss in Response to Diet Interventions: The POUNDS Lost Trial
Authors: Dianjianyi Sun, Yoriko Heianza, Xiang Li, Xiaoyun Shang, Steven R Smith, George A Bray, Frank M Sacks, Lu Qi
Journal: Circulation (2017)

Background: Methylation of NFATC2I was identified to be causally related to body mass index. We examined the roles of the genetic variation, DNA methylation, and gene expression at this locus in ad...
The Randomized Study Comparing the Efficacy and Safety of Radio-Chemotherapy Plus Adjuvant Chemotherapy (CCRT) Vs. Neo-Adjuvant Chemotherapy Plus Radio-Chemotherapy (NAC-RT) for Locally Advanced Nasopharyngeal Cancer
Authors: S. Chakrabandhu, I. Chitapanarux, R. Jiratrachu, K. Pruegsanusak, A. Pinitpatcharalerd, J. Sukhaboon, C. Tovanabutra, A. Srisuthep, N. Prasongsook, V. Lorvidhaya
Journal: Annals of Oncology (2012)
Increased Cerebral Metabolic Stress Is Associated with Diminished Functional Connectivity in Pediatric Sickle Cell Anemia
Authors: Melanie E Fields, Amy Mirro, Kristin P Guilliams, Michael M Binkley, Cihat Eldeniz, Slim Fellah, Andria L Ford, Yasheng Chen, Allison A. King, Hongyu An, Christopher Smyser, Jin-Moo Lee
Journal: Blood (2019)
Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans
Authors: Gwladys Gernoux, Alisha M. Gruntman, Meghan Blackwood, Marina Zieger, Terence R. Flotte, Christian Mueller
Journal: Molecular Therapy (2020)

With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zolgensma, Luxturna, and Glybera, recombinant adeno-associated viruses (rAAVs) are considered efficient tools for gene transfer. However, studies in animals and humans demonstrate that intramuscular (IM) AAV delivery can trigger immune responses to AAV capsids and/or transgenes. IM delivery of rAAV1 in humans has also been described to induce tolerance to rAAV characterized by the presence of capsid-specific regulatory T cells (Tregs) in periphery. To understand mechanisms responsible for tolerance and parameters involved, we tested 3 muscle-directed administration routes in rhesus monkeys: IM delivery, venous limb perfusion, and the intra-arterial push and dwell method. These 3 methods were well tolerated and led to transgene expression. Interestingly, gene transfer in muscle led to Tregs and exhausted T cell infiltrates in situ at both day 21 and day 60 post-injection. In human samples, an in-depth analysis of the functionality of these cells demonstrates that capsid-specific exhausted T cells are detected after at least 5 years post-vector delivery and that the exhaustion can be reversed by blocking the checkpoint pathway. Overall, our study shows that persisting transgene expression after gene transfer in muscle is mediated by Tregs and exhausted T cells. With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zolgensma, Luxturna, and Glybera, recombinant adeno-associated viruses (rAAVs) are considered efficient tools for gene transfer. However, studies in animals and humans demonstrate that intramuscular (IM) AAV delivery can trigger immune responses to AAV capsids and/or transgenes. IM delivery of rAAV1 in humans has also been described to induce tolerance to rAAV characterized by the presence of capsid-specific regulatory T cells (Tregs) in periphery. To understand mechanisms responsible for tolerance and parameters involved, we tested 3 muscle-directed administration routes in rhesus monkeys: IM delivery, venous limb perfusion, and the intra-arterial push and dwell method. These 3 methods were well tolerated and led to transgene expression. Interestingly, gene transfer in muscle led to Tregs and exhausted T cell infiltrates in situ at both day 21 and day 60 post-injection. In human samples, an in-depth analysis of the functionality of these cells demonstrates that capsid-specific exhausted T cells are detected after at least 5 years post-vector delivery and that the exhaustion can be reversed by blocking the checkpoint pathway. Overall, our study shows that persisting transgene expression after gene transfer in muscle is mediated by Tregs and exhausted T cells.
Safety and Efficacy of Proton-Beam Radiation Therapy for Patients with Locally Recurrent rectal Cancer
Authors: S. Hamauchi, K. Yamazaki, H. Yasui, N. Boku, Y. Onozawa, A. Fukutomi, N. Machida, T. Yokota, A. Todaka, H. Taniguchi, T. Tsushima, T. Funakoshi, H. Tabuse, Y. Shibata
Journal: Annals of Oncology (2012)
Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials
Authors: C. Lebbe, J.S. Weber, M. Maio, B. Neyns, K. Harmankaya, K. Chin, D. Opatt McDowell, L. Cykowski, M.B. McHenry, J.D. Wolchok
Journal: Annals of Oncology (2012)
Evaluation of the Quality of Life and Economic Burden with Granulocyte-Colony Stimulating Factor in Chinese Breast Cancer Patients Receiving Docetaxel, Epirubicin and Cyclophosphamide
Authors: M. He, S. Huang, L. Yu, G. Shi, J. Deng, X. Zhang, X. Wang, J. Chen, X. Nong, P. Shen
Journal: Annals of Oncology (2012)
PD-0015 Influence of BRAF V600E and Different Kras Mutations on Outcome of Metastatic Colorectal Cancer Patients Treated with First- Line Therapy
Authors: Martina Rebersek, Marko Boc, Zvezdana Hlebanja, Neva Volk, Jernej Benedik, Maja Ebert, Tanja Mesti, Janja Ocvirk
Journal: Annals of Oncology (2012)
Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet)
Authors: M. Andersson, J.M. Lopez-Vega, L. Del Mastro, T. Petit, L. Mitchell, C. Pelizon, E.A. Perez
Journal: Annals of Oncology (2012)
Racial Disparities in Readmission Rates Following Acute Myocardial Infarction in the Hospital Readmissions Reduction Program Era
Authors: Martha J. Radford
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
P-0265 Msi+ Stage II/III Colon Cancer Patients Benefit from Capecitabine Adjuvant Monotherapy
Authors: Aleksandar Dimovski, Nadica Matevska, Aleksandar Eftimov, Aleksandra Kapedanovska Nestorovska, Natalija Angelovska Petrusevska, Biljana Angelovska, Djingis Jashar, Nikola Mitrevski, Toni Josifovski
Journal: Annals of Oncology (2012)
Determining patient understanding of commonly used dermatology terms: A multicenter cross-sectional survey
Authors: Brett C. Neill, Nicholas Golda, Edward W. Seger, Jo Wick, Jacob Whitsitt, Alison Huber, Thomas Chu, Geoffrey A. Potts, Peter Chow, Sarah Moore, Joseph W. Fakhoury, Anand Rajpara, Thomas L.H. Hocker
Journal: Journal of the American Academy of Dermatology (2020)
P1.31 Snp Q787Q of Egfr Gene and Efficacy of Egfr-Tki in Patients With Non-Small Cell Lung Cancer
Authors: Y.C Kim, T Jang, I.J. Oh, K.S Kim, H. Ban, K.J. Na, S.J Ahn, H Kang, W.J Kim, C Park
Journal: Annals of Oncology (2012)
Phase I/II Trial of Lenvatinib (E7080), A Multi-Targeted Tyrosine Kinase Inhibitor, in Patients (PTS) with advanced Hepatocellular Carcinoma (HCC)
Authors: K. Ikeda, H. Kumada, M. Kudo, S. Kawazoe, Y. Osaki, M. Ikeda, T. Okusaka, T. Suzuki, J.P. O'Brien, K. Okita
Journal: Annals of Oncology (2012)
Comparative Study Between Belotecan/Cisplatin and Etoposide/Cisplatin (COMBAT) in Patients with Previously Untreated, Extensive Stage Small Cell Lung Cancer - Interim Analysis
Authors: Y. Kim, K. Kim, I. Oh, H. Ban, K. Na, S. Ahn, H. Kang, W. Kim, C. Park, S. Yang
Journal: Annals of Oncology (2012)
Edmonton Symptom Assessment Scale (ESAS) For Routine Symptom Assessment of Non-Advanced Patients with Solid or Haematological Malignancies on Oncological Therapies
Authors: C.I. Ripamonti, S. Boldini, L. Buonaccorso, E. Bandieri, A. Maruelli, M.A. Pessi, G. Miccinesi
Journal: Annals of Oncology (2012)
Costs, Benefits, and Sacred Values — Why Health Care Reform Is So Fraught
Authors: Lisa Rosenbaum
Journal: New England Journal of Medicine (2020)

Interview with Dr. David Cutler on the debate over Medicare for All and other proposals for reforming the U.S. health care system. (11:18)Download As debate about U.S health care begins anew, with particular focus on a “Medicare for All” type insurance design, it’s worth considering why weighing the complex but real trade-offs involved in health policy remains so politically challenging.
First-in-Human Experience With Peritoneal Direct Sodium Removal Using a Zero-Sodium Solution
Authors: Veena S. Rao, Jeffrey M. Turner, Matthew Griffin, Devin Mahoney, Jennifer Asher, Sangchoon Jeon, Peter S. Yoo, Nabil Boutagy, Attila Feher, Albert Sinusas, F. Perry Wilson, Fredric Finkelstein, Jeffrey M. Testani
Journal: Circulation (2020)

Loop diuretics have well-described toxicities, and loss of response to these agents is common. Alternative strategies are needed for the maintenance of euvolemia in heart failure (HF). Nonrenal removal of sodium directly across the peritoneal membrane (direct sodium removal [DSR]) with a sodium-free osmotic solution should result in extraction of large quantities of sodium with limited off-target solute removal.This article describes the preclinical development and first-in-human proof of concept for DSR. Sodium-free 10% dextrose was used as the DSR solution. Porcine experiments were conducted to investigate the optimal dwell time, safety, and scalability and to determine the effect of experimental heart failure. In the human study, participants with end-stage renal disease on peritoneal dialysis (PD) underwent randomization and crossover to either a 2-hour dwell with 1 L DSR solution or standard PD solution (Dianeal 4.25% dextrose, Baxter). The primary end point was completion of the 2-hour dwell without significant discomfort or adverse events, and the secondary end point was difference in sodium removal between DSR and standard PD solution.Porcine experiments revealed that 1 L DSR solution removed 4.1±0.4 g sodium in 2 hours with negligible off-target solute removal and overall stable serum electrolytes. Increasing the volume of DSR solution cycled across the peritoneum increased sodium removal and substantially decreased plasma volume (P=0.005). In the setting of experimental heart failure with elevated right atrial pressure, sodium removal was ≈4 times greater than in healthy animals (P<0.001). In the human proof-of-concept study, DSR solution was well tolerated and not associated with significant discomfort or adverse events. Plasma electrolyte concentrations were stable, and off-target solute removal was negligible. Sodium removal was substantially higher with DSR (4.5±0.4 g) compared with standard PD solution (1.0±0.3 g; P<0.0001).DSR was well tolerated in both animals and human subjects and produced substantially greater sodium removal than standard PD solution. Additional research evaluating the use of DSR as a method to prevent and treat hypervolemia in heart failure is warranted. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03801226.
Abstract 12572: Can the LAAOS Score Predict Recurrence IiPatients Undergoing Persistent Atrial Fibrillation Ablation? A Pilot Study
Authors: Jose Henao, Sokol Kalaveshi, Stephen Mester, Christian Perzanowski
Journal: Circulation (2019)

Introduction/Hypothesis: Radiofrequency ablation to treat Persistent Atrial Fibrillation (PeAF) has grown exponentially; predicting outcomes has been challenging. We developed and hypothesized that...
Phase III Study Comparing Second- and Third-Generation Regimens with Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: An Additional Analysis by the Histological Type in the WJTOG0105 Study
Authors: M. Satouchi, Y. Chiba, N. Yamamoto, Y. Nishimura, K. Tsujino, Y. Fujisaka, S. Kudoh, T. Hida, S. Atagi, K. Nakagawa
Journal: Annals of Oncology (2012)
Treatment Patterns in Patients with Metastatic Soft Tissue Sarcoma (STS). Results from an Exhaustive Cohort in Rhone-Alpes Region (France), the EMS (Medical Evaluation of Sarcoma) Study
Authors: O. Collard, B. Tehard, I. Ray-Coquard, N. Ladarre, S. Manson, F. Ducimetiere, M. Laramas, J. Blay
Journal: Annals of Oncology (2012)
Paclitaxel/Carboplatin Chemotherapy as Salvage Treatment in Metastatic Melanoma: Is Non-Cutaneous Melanoma Different?
Authors: W. Chang, J. Lee, S.J. Lee, S. Park, M.K. Choi, J.Y. Hong, Y.S. Kim, C.H. Maeng, S. Kim
Journal: Annals of Oncology (2012)
A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients with HER-2 Positive Advanced Gastric Cancer After Failure of at Least one Prior Chemotherapy Regimen
Authors: K.-H. Lee, D.-Y. Oh, K.-W. Lee, J.Y. Cho, W.K. Kang, S.Y. Rha, Y.-J. Bang
Journal: Annals of Oncology (2012)
A Phase II Trial of Gemcitabine for Chemo-Naive Metastatic Pancreatic Endocrine Tumor
Authors: C. Morizane, H. Ueno, S. Kondo, S. Mitsunaga, S. Shimizu, I. Ohno, H. Takahashi, T. Yamaguchi, Y. Sakamoto, T. Okusaka
Journal: Annals of Oncology (2012)
Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer (NSCLC): Results of the First Intern Round Robin Panel Testing (8 Institutes from Germany and SWITZERLAND)
Authors: M. von Laffert, P. Schirmacher, H. Kreipe, R. Büttner, I. Petersen, W. Jochum, M. Dietel, M. Hummel
Journal: Annals of Oncology (2012)